Lung cancer is among the cancers with the highest incidence in the world, of which about 80% of patients are non-small cell lung cancer, mainly because there are no obvious symptoms at an early stage, usually diagnosed at a clinically advanced stage, and the prognosis is extremely poor. Surgery, radiotherapy, chemotherapy, and targeted therapy are the traditional treatment methods for lung cancer, which cannot fully meet the needs of clinical treatment. In recent years, immunotherapy has become the focus of lung cancer treatment.
The immune checkpoint is a kind of immunosuppressive molecule that can regulate the body's immune activation. The abnormal expression and function of the immune checkpoint is one of the important causes of lung cancer. Therefore, repairing immune checkpoint abnormalities has become an important option for cancer treatment. Programmed death receptor 1 (PD-1), programmed death ligand 1 (PD-L1), and T cell mucin immunoglobulin 3 (TIM-3) are common checkpoints of the immune system.
In recent years, the application of immune checkpoint inhibitors (ICIs) in lung cancer has made great progress, which has brought long-term survival benefits to some lung cancer patients. However, some patients who received ICIs had no effect or transient benefit, suggesting the existence of primary and secondary immune resistance. The mechanism of immunotherapy resistance is very complex, and how to overcome drug resistance and find new therapeutic targets is an important problem. At present, combination therapies are used to delay or prevent the development of resistance to immune checkpoint inhibitors (ICI), including blocking immunosuppressive signals, activating stimulatory signals, regulating the immune microenvironment, and targeting T cells. It is promising to specify different therapies to treat lung cancer according to different biological resistance mechanisms. Therefore, further research is still needed to better integrate immune checkpoint inhibitors with the treatment of lung cancer, optimize the current treatment methods of lung cancer, and improve clinical outcomes.
In this Research Topic, we welcome submissions of both Original Research and Review articles including but not limited to the following:
• Research progress of immune checkpoint inhibitors in lung cancer
• Novel Immune Checkpoint Inhibitors for Lung Cancer
• Mechanism of immune checkpoint inhibitor resistance in lung cancer
• Immune checkpoint inhibitors improve the prognosis of lung cancer patients with targeted drug resistance
• A rational systemic regimen of immune checkpoint inhibitors for the treatment of lung cancer
• Side effects of ICI for lung cancer
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Lung cancer is among the cancers with the highest incidence in the world, of which about 80% of patients are non-small cell lung cancer, mainly because there are no obvious symptoms at an early stage, usually diagnosed at a clinically advanced stage, and the prognosis is extremely poor. Surgery, radiotherapy, chemotherapy, and targeted therapy are the traditional treatment methods for lung cancer, which cannot fully meet the needs of clinical treatment. In recent years, immunotherapy has become the focus of lung cancer treatment.
The immune checkpoint is a kind of immunosuppressive molecule that can regulate the body's immune activation. The abnormal expression and function of the immune checkpoint is one of the important causes of lung cancer. Therefore, repairing immune checkpoint abnormalities has become an important option for cancer treatment. Programmed death receptor 1 (PD-1), programmed death ligand 1 (PD-L1), and T cell mucin immunoglobulin 3 (TIM-3) are common checkpoints of the immune system.
In recent years, the application of immune checkpoint inhibitors (ICIs) in lung cancer has made great progress, which has brought long-term survival benefits to some lung cancer patients. However, some patients who received ICIs had no effect or transient benefit, suggesting the existence of primary and secondary immune resistance. The mechanism of immunotherapy resistance is very complex, and how to overcome drug resistance and find new therapeutic targets is an important problem. At present, combination therapies are used to delay or prevent the development of resistance to immune checkpoint inhibitors (ICI), including blocking immunosuppressive signals, activating stimulatory signals, regulating the immune microenvironment, and targeting T cells. It is promising to specify different therapies to treat lung cancer according to different biological resistance mechanisms. Therefore, further research is still needed to better integrate immune checkpoint inhibitors with the treatment of lung cancer, optimize the current treatment methods of lung cancer, and improve clinical outcomes.
In this Research Topic, we welcome submissions of both Original Research and Review articles including but not limited to the following:
• Research progress of immune checkpoint inhibitors in lung cancer
• Novel Immune Checkpoint Inhibitors for Lung Cancer
• Mechanism of immune checkpoint inhibitor resistance in lung cancer
• Immune checkpoint inhibitors improve the prognosis of lung cancer patients with targeted drug resistance
• A rational systemic regimen of immune checkpoint inhibitors for the treatment of lung cancer
• Side effects of ICI for lung cancer
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
